. Author manuscript; available in PMC: 2013 Aug 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2011 Dec 23;18(8):1255–1264. doi: 10.1016/j.bbmt.2011.12.581

Table 2.

Univariate outcome probabilities

Outcome event	Prob. (95% CI)^a
30 day mortality	10 (7–15)
100 day mortality	30 (25–36)
Absolute neutrophil count>0.5 × 10⁹/L
@ 28 days	91 (87–95)
@ 100 days	95 (92–97)
Acute GVHD @ 100 days, grades (2–4)	39 (34–45)
Chronic GVHD
@ 1 year	37 (31–43)
@ 3 years	40 (34–46)
@ 5 years	40 (34–46)
NRM
@ 1 year	39 (33–45)
@ 3 years	44 (37–50)
@ 5 years	47 (40–53)
Progression/relapse
@ 1 year	31 (25–36)
@ 3 years	35 (29–41)
@ 5 years	36 (30–42)
PFS
@ 1 year	30 (25–36)
@ 3 years	21 (16–27)
@ 5 years	17 (13–22)
Overall survival
@ 1 year	44 (38–50)
@ 3 years	32 (27–38)
@ 5 years	27 (21–32)

Probabilities of neutrophil, acute and chronic GVHD, NRM, and progression/relapse were calculated using the cumulative incidence estimate. 100-day mortality, PFS and overall survival were calculated using the Kaplan-Meier product limit estimate.